Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

SciClone Pharmaceuticals Inc (NASDAQ:SCLN)

10.25
Delayed Data
As of 11:36am ET
 +0.10 / +0.99%
Today’s Change
7.37
Today|||52-Week Range
15.03
+11.41%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$518.2M

Company Description

SciClone Pharmaceuticals, Inc. engages in the development of therapeutics treatment for cancer, infectious diseases, and cardiovascular disorders. Its product portforlio includes ZADAXIN, Holxan, Mesna, Endoxan, Farlutal, Methotrexate. Estracyt, Neucardin, Loramyc, and DC Bead. The company was founded in 1990 and is headquartered in Foster City, CA.

Contact Information

SciClone Pharmaceuticals, Inc.
950 Tower Lane
Foster City California 94404-2125
P:(650) 358-3456
Investor Relations:

Employees

Shareholders

Mutual fund holders44.24%
Other institutional33.87%
Individual stakeholders15.86%

Top Executives

Friedhelm BlobelPresident, Chief Executive Officer & Director
Wai-Shun Wilson CheungChief Financial Officer, Secretary & SVP-Finance
Robert S. KingVice President-Product Development & Manufacturing
Lan XieChief Financial Officer-China Operations
Hong ZhaoChief Executive Officer-China Operations